
    
      The relapsed and/or refractory B-ALL patients will receive infusions of allogeneic CART-19
      within 1 week after chemotherapy. The re-induction chemotherapy regimen was primarily
      vindesine, mitoxantrone, cyclophosphamide, pegaspargase and dexamethasone, and no
      graft-versus-host disease (GVHD) prevention was conducted pre- and post- therapy.
    
  